Characteristics and disease course of untreated patients with interstitial lung disease associated with systemic sclerosis in a real-life two-centre cohort
Background Interstitial lung disease (ILD) is the leading cause of death in systemic sclerosis (SSc). According to expert statements, not all SSc-ILD patients require pharmacological therapy.Objectives To describe disease characteristics and disease course in untreated SSc-ILD patients in two well c...
Saved in:
| Main Authors: | Oliver Distler, Cosimo Bruni, Anna-Maria Hoffmann-Vold, Suzana Jordan, Carina Mihai, Muriel Elhai, Marouane Boubaya, Rucsandra Dobrota, Øyvind Midtvedt, Mike Becker, Alexandru Garaiman, Håvard Fretheim, Imon Barua, Moritz Scheidegger, Hilde Jenssen Bjørkekjær |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2024-02-01
|
| Series: | RMD Open |
| Online Access: | https://rmdopen.bmj.com/content/10/1/e003658.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Validation of a semi-quantitative method to assess interstitial lung disease severity and progression in systemic sclerosis by standard and low-dose HRCT scans
by: Thomas Frauenfelder, et al.
Published: (2025-02-01) -
Does therapy with immunosuppressive drugs improve gastrointestinal symptoms in patients with systemic sclerosis?
by: Oliver Distler, et al.
Published: (2024-07-01) -
Performance of the EULAR Systemic sclerosis Impact of Disease (ScleroID) questionnaire as a patient-reported outcome measure for patients with diffuse systemic sclerosis
by: Ulf Mueller-Ladner, et al.
Published: (2024-11-01) -
Noninvasive, Multimodal Inflammatory Biomarker Discovery for Systemic Inflammation (NOVA Study): Protocol for a Cross-Sectional Study
by: Jinjoo Shim, et al.
Published: (2024-11-01) -
Rationale for phosphodiesterase-4 inhibition as a treatment strategy for interstitial lung diseases associated with rheumatic diseases
by: Elizabeth R Volkmann, et al.
Published: (2024-12-01)